News

The increase in net losses for the year is attributable to increased expenditures in research and development of products in the company’s pipeline and to accounting requirements for

Revenues for the fourth quarter were $35.7 million compared to $33.7 million in the third quarter, 2007, an increase of 6% quarter on quarter. Excluding the impact of

Net loss for the 12-month period decreased to $2 million or $0.04 per share in 2007 from $3.4 million or $0.07 per share in 2006, due to better

For the year ended December 31, 2007, the company reported a net loss of $34.8 million ($0.57 loss per share) compared to a net loss of $23.1 million

For the fiscal year ended December 31, 2007, the company reported a net loss of $25 million, or $0.31 per share, compared to a net loss of $18

For the full year, Cytogen reported a net loss of $25.7 million, or $0.79 per diluted share in 2007, compared to a net loss of $15.1 million, or

Under the terms of the settlement, the pending action will be dismissed with prejudice and without any admission of liability on the part of the company or any

The trial is designed to evaluate the safety and efficacy of ARC1779 as a first-in-class anti-platelet agent in patients suffering from life-threatening blood disorder known as thrombotic thrombocytopenic

BioMerieux and Hitachi High-Technologies will work together to identify and develop new systems. The new instruments developed under this partnership will be manufactured by Hitachi High-Technologies and distributed